Is the Vanguard Mega Cap ETF the Simplest Way to Invest in the Top S&P 500 Stocks? Investors looking to double down on mega cap stocks like the "Ten Titans" may want to take a closer look at this low-cost ETF.
Warren Buffett Makes a Big Buy Berkshire Hathaway bought $1.6 billion of United Health stock in Q2. Inflation may be ticking higher after all.
Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock.
Here's Why Shares in Viking Therapeutics Crashed This Week The phase 2 trial results for its key drug didn't pan out quite as planned.
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. The tariffs will impact products imported from Europe, the Trump administration said late Thursday.
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs Johnson & Johnson (
NYSE: JNJ ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? A disappointing result for its oral obesity candidate hammered the stock price.
Here's Why Viking Therapeutics Bounced Back Today Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (
NYSE: PLTR ) and Viking Therapeutics (
NASDAQ: VKTX ), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.
Is the Vanguard Dividend Appreciation ETF a Buy Now? This stalwart ETF offers a little bit of everything and could outperform the S&P 500 if the Magnificent Seven stocks tumble.
One of the Best Stocks to Buy Now? I ranked Eli Lilly as one of the best stocks to buy starting in 2025.
What's Going on With Eli Lilly Stock? The pharma company is gaining investor attention due to increasingly popular products.
Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior.
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns San Diego, CA – Viking Therapeutics (
NASDAQ: VKTX ) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive.
Why Novo Nordisk Stock Popped Today For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.
